Literature DB >> 17172842

Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma.

Chi L Braunreiter1, Jeffrey D Hancock, Cheryl M Coffin, Kenneth M Boucher, Stephen L Lessnick.   

Abstract

Ewing's sarcomas contain specific chromosomal translocations that fuse EWS to ETS family members, including FLI, ERG, FEV, ETV1 and ETV4. Prior work has suggested that functional differences exist between some of these EWS-ETS fusions. However, as the cell of origin of Ewing's sarcoma is unknown, this prior work was conducted in NIH3T3 cells, which have not been validated as an appropriate model for the study of EWS-ETS fusions. To determine if NIH3T3 cells are a good model for Ewing's sarcoma, we introduced all five EWS-ETS fusions into these cells, and analyzed their phenotypes and gene expression patterns. EWS-FLI, EWS-ERG, and EWS-FEV caused NIH3T3 cells to exhibit anchorage independent growth whereas EWS-ETV1 and EWS-ETV4 did not. In contrast, all the EWS-ETS fusions induced tumor formation in a xenograft model. We defined the core transcriptional profile of the EWS-ETS fusions using cDNA microarrays, and compared these to data derived from patient-derived Ewing's sarcoma cell lines. The NIH3T3 model did not recapitulate the gene expression pattern of bona fide Ewing's sarcoma. Based on these results, we conclude that while there may be functional differences between the various EWS-ETS fusions, the NIH3T3 cell model is inadequate to study the gene expression pattern induced by EWS-ETS proteins in Ewing's sarcoma. Thus, data derived from the NIH3T3 model system needs to be appropriately validated before they can be accepted as relevant to the human disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17172842     DOI: 10.4161/cc.5.23.3505

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  37 in total

Review 1.  Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.

Authors:  Stephen L Lessnick; Marc Ladanyi
Journal:  Annu Rev Pathol       Date:  2011-09-19       Impact factor: 23.472

2.  Molecular biology and therapeutics in musculoskeletal oncology.

Authors:  Theresa A Guise; Regis O'Keefe; R Lor Randall; Richard M Terek
Journal:  J Bone Joint Surg Am       Date:  2009-03-01       Impact factor: 5.284

Review 3.  Promiscuous partnerships in Ewing's sarcoma.

Authors:  Savita Sankar; Stephen L Lessnick
Journal:  Cancer Genet       Date:  2011-07

Review 4.  Ewing sarcoma/peripheral primitive neuroectodermal tumor and related tumors.

Authors:  Maria Tsokos; Rita D Alaggio; Louis P Dehner; Paul S Dickman
Journal:  Pediatr Dev Pathol       Date:  2012

5.  EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

Authors:  Jason M Tanner; Claire Bensard; Peng Wei; Nathan M Krah; John C Schell; Jamie Gardiner; Joshua Schiffman; Stephen L Lessnick; Jared Rutter
Journal:  Mol Cancer Res       Date:  2017-07-18       Impact factor: 5.852

6.  A novel role for keratin 17 in coordinating oncogenic transformation and cellular adhesion in Ewing sarcoma.

Authors:  Savita Sankar; Jason M Tanner; Russell Bell; Aashi Chaturvedi; R Lor Randall; Mary C Beckerle; Stephen L Lessnick
Journal:  Mol Cell Biol       Date:  2013-09-16       Impact factor: 4.272

7.  EWS/FLI-1 induces rapid onset of myeloid/erythroid leukemia in mice.

Authors:  Enrique C Torchia; Kelli Boyd; Jerold E Rehg; Chunxu Qu; Suzanne J Baker
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

8.  Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.

Authors:  Ashley A Kowalewski; R Lor Randall; Stephen L Lessnick
Journal:  Sarcoma       Date:  2010-11-01

9.  Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth.

Authors:  Savita Sankar; Emily R Theisen; Jared Bearss; Timothy Mulvihill; Laura M Hoffman; Venkataswamy Sorna; Mary C Beckerle; Sunil Sharma; Stephen L Lessnick
Journal:  Clin Cancer Res       Date:  2014-06-24       Impact factor: 12.531

10.  A molecular function map of Ewing's sarcoma.

Authors:  Maximilian Kauer; Jozef Ban; Reinhard Kofler; Bob Walker; Sean Davis; Paul Meltzer; Heinrich Kovar
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.